tumor-infiltrating lymphocytes + interleukin-7

**Tumor-infiltrating lymphocytes + interleukin-7** is a nonstandard combination immunotherapy concept that pairs adoptive transfer of autologous tumor-infiltrating lymphocytes with exogenous interleukin-7 support. TIL therapy works by isolating lymphocytes from a patient's tumor, expanding tumor-reactive T cells ex vivo, and reinfusing them to mediate direct antitumor cytotoxicity; IL-7 is a homeostatic cytokine that signals primarily through the interleukin-7 receptor complex to promote T-cell survival, expansion, and memory differentiation. In principle, adding IL-7 could improve persistence and fitness of transferred T cells while avoiding some liabilities of interleukin-2, but the exact product configuration, developer, manufacturing process, and clinical development status are not identifiable from the queried name alone. Accordingly, this entry is best treated as a nonspecific combination regimen concept rather than a single well-defined commercial drug product.

Other names

tumor-infiltrating lymphocytes + interleukin-7tumor infiltrating lymphocytes + interleukin-7TIL + IL-7TIL therapy + IL-7